Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Harvard Business School
Mallinckrodt
McKinsey
AstraZeneca

Last Updated: August 19, 2022

LATISSE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Latisse, and when can generic versions of Latisse launch?

Latisse is a drug marketed by Allergan and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has seventeen patent family members in eight countries.

The generic ingredient in LATISSE is bimatoprost. There are twelve drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Latisse

A generic version of LATISSE was approved as bimatoprost by APOTEX INC on December 1st, 2014.

  Try it Free

Drug patent expirations by year for LATISSE
Drug Prices for LATISSE

See drug prices for LATISSE

Recent Clinical Trials for LATISSE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AllerganEarly Phase 1
Tulane UniversityEarly Phase 1
AllerganPhase 3

See all LATISSE clinical trials

Pharmacology for LATISSE
Paragraph IV (Patent) Challenges for LATISSE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
LATISSE Topical Solution bimatoprost 0.03% 022369 1 2010-05-03

US Patents and Regulatory Information for LATISSE

LATISSE is protected by nine US patents.

Patents protecting LATISSE

Method of enhancing hair growth
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS

Method of enhancing hair growth
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF INCREASING HAIR GROWTH

Method of enhancing hair growth
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF STIMULATING HAIR GROWTH

Method of enhancing hair growth
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN

Method of enhancing hair growth
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF INCREASING EYELASH GROWTH

Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF INCREASING EYELASH GROWTH

Method of enhancing hair growth
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF INCREASING HAIR GROWTH

Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF INCREASING EYELASH GROWTH

Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF INCREASING GROWTH OF HAIR INCLUDING EYELASHES

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LATISSE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 See Plans and Pricing See Plans and Pricing
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 See Plans and Pricing See Plans and Pricing
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 See Plans and Pricing See Plans and Pricing
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for LATISSE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
AbbVie Deutschland GmbH & Co. KG Lumigan bimatoprost EMEA/H/C/000391
Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).,
Authorised no no no 2002-03-08
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Supplementary Protection Certificates for LATISSE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0660716 SPC/GB02/035 United Kingdom See Plans and Pricing PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308
0660716 90957 Luxembourg See Plans and Pricing
0660716 C300099 Netherlands See Plans and Pricing PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
0660716 02C0033 France See Plans and Pricing PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Colorcon
McKesson
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.